share_log

IntegriChain Revenue Optimization Experts to Speak at Informa's Pharma/BioTech GTN Summit

IntegriChain Revenue Optimization Experts to Speak at Informa's Pharma/BioTech GTN Summit

IntegriChain營業收入優化專家將在Informa的Pharma/BioTech GTN峯會上發表演講
PR Newswire ·  11/11 22:14

PHILADELPHIA, Nov. 11, 2024 /PRNewswire/ -- IntegriChain, the leading provider of pharma revenue optimization technology and insights for the pharmaceutical industry, today announced that its revenue optimization experts will present at Informa's upcoming Pharma | Biotech GTN Summit November 18 to 20 in Philadelphia. Jen Sharpe, Vice President of Gross-to-Net Consulting and facilitator of the Revenue Analytics Collaborative, and Jeff Baab, Partner, Advisory Services, have extensive experience in revenue optimization strategies and execution and GTN automation for Pharma manufacturers of all sizes, business stages, and complexity.

費城,2024年11月11日 /PRNewswire/ — 製藥行業領先的製藥收入優化技術和見解提供商IntegricHain今天宣佈,其收入優化專家將出席即將舉行的Informa會議 製藥 | 生物技術 GTN 峯會 11 月 18 日至 20 日在費城。 詹·夏普,淨收入諮詢副總裁兼收入分析合作組織主持人,以及 傑夫·巴布,諮詢服務合作伙伴,在爲各種規模、業務階段和複雜性的製藥製造商提供收入優化策略和執行以及GTN自動化方面擁有豐富的經驗。

Details of IntegriChain's sessions during the conference are as follows.

IntegriChain在會議期間的會議詳情如下。

Revenue Analytics Collaborative Hot Topics
Monday, November 18, 4:30 - 6:00 pm ET
Jen Sharpe, VP, GTN Consulting

收入分析合作熱門話題
美國東部時間 11 月 18 日星期一下午 4:30-6:00
GTN 諮詢副總裁 Jen Sharpe

Sharpe will host and moderate a roundtable discussion for the members of the Revenue Analytics Collaborative, a private, anonymous network of business and financial professionals, who own, support, and analyze Commercial, Government, Gross-to-Net (GTN), and Trade/Channel data, processes, and systems in Pharma companies, as well as any interested conference attendees. Attendees can choose discussions in the following hot-topic areas, including some of the unprecedented challenges facing the industry today, to gain insights from participating industry experts and peers.

夏普將爲成員主持和主持圓桌討論 收入分析協作,一個由商業和金融專業人員組成的私人匿名網絡,他們擁有、支持和分析製藥公司的商業、政府、總淨值(GTN)和貿易/渠道數據、流程和系統,以及任何感興趣的與會者。與會者可以選擇以下熱門話題領域的討論,包括當今行業面臨的一些前所未有的挑戰,以從參與的行業專家和同行那裏獲得見解。

  • Government Impacts on GTN: IRA Part D/B Rebates, MFP & AMP Cap Removal
  • Coverage Gap Redesign: Successful Predictive Modeling
  • GTN Monthly Close: Successful Practices & Methodologies
  • All Things 340B: Analyzing Revenue Leakage and Tackling Contract Pharmacies
  • Wrangling GTN Data Sources: 3PL, Copay Vendor, ERP, Adjudication Application
  • Patient & Access Program Impact on GTN: Copay, Bridge, Voucher, Digital Pharmacies
  • Payer Pressures on GTN: Understanding Shifts in Rebates, Admin Fees, and Price Protection Protection
  • Demand and Inventory Management: Reconciling Pipeline against Sales and Demand
  • Product Launch: Successful GTN Roadmap to Launch
  • Returns: Successful Vendors, Analogs, and Methodologies
  • 政府對GTN的影響:IRA第d/b部分返利、MFP和AMP上限的取消
  • 覆蓋範圍差距重新設計:成功的預測建模
  • GTN月度收盤:成功實踐與方法
  • All Things 340B:分析收入流失和處理合同藥房問題
  • 整理GTN數據源:3PL、自付供應商、ERP、裁決應用程序
  • 患者與准入計劃對GTN的影響:自付費、過橋費、代金券、數字藥房
  • 付款人對GTN的壓力:了解返利、管理費和價格保護的變化
  • 需求和庫存管理:協調管道與銷售和需求
  • 產品發佈:成功的GTN發佈路線圖
  • 回報:成功的供應商、類似物和方法

Evolution and Scalability for Clinical to Commercial Preparedness
Jen Sharpe, VP, GTN Consulting
Chris Prentiss, Chief Financial Officer, Mannkind
Tuesday, November 19, 3:45 - 5:00 pm ET

臨床到商業準備的演變和可擴展性
GTN 諮詢副總裁 Jen Sharpe
Chris Prentiss,Mannkind 首席財務官
美國東部時間 11 月 19 日星期二下午 3:45-5:00

In this session, Sharpe and Prentiss will share their revenue optimization expertise for emerging Pharma companies as they prepare for commercialization. They will share their combined top-10 list for launch considerations along with operational best practices and pain points and challenges to overcome. Focusing on these younger companies, they will share how to build on the initial launch and considerations for management of additional processes and analyses – all while managing scalability in Finance departments and growing companies. Lastly, they will explore post-launch expectations in the near- and long-term.

在本次會議中,夏普和普倫蒂斯將分享他們在新興製藥公司爲商業化做準備時的收入優化專業知識。他們將分享其合併後的前十名名單,以供發佈考慮以及最佳運營實踐以及需要克服的痛點和挑戰。他們將重點關注這些年輕的公司,分享如何在首次啓動的基礎上再接再厲,以及管理其他流程和分析的注意事項,同時管理財務部門和成長型公司的可擴展性。最後,他們將探討發佈後的短期和長期預期。

Evaluating the Impact of Medicare Negotiation and Healthcare Policy Updates
Jeff Baab, Partner, Advisory Services, IntegriChain
Wednesday, November 20, 9:30 - 10:15 am ET

評估醫療保險談判和醫療保健政策更新的影響
傑夫·巴布,IntegricHain 諮詢服務合夥人
美國東部時間 11 月 20 日星期三上午 9:30-10:15

From Medicare negotiation to a new CMS Final Rule to the popping of the proverbial gross-to-net bubble, the volume and magnitude of changes impacting pricing, contracting and market access decisions continues to unfold at an unprecedented pace. In this session, Baab will explore how the multitude of market events, landmark policy decisions, and stakeholder reactions are influencing how Pharma stakeholders will continue to evolve and react and how it may impact GTN.

從醫療保險談判到新的CMS最終規則,再到衆所周知的總淨泡沫的破滅,影響定價、合同和市場準入決策的變化的數量和規模繼續以前所未有的速度展開。在本次會議中,Baab將探討衆多市場事件、具有里程碑意義的政策決策和利益相關者的反應如何影響製藥利益相關者的繼續演變和反應,以及它可能如何影響GTN。

About IntegriChain's Advisory Services
IntegriChain is a drug commercialization partner to a wide range of pharmaceutical manufacturers. From helping emerging companies plan and execute their first-time launch to supporting more than 65% of the top-50 largest manufacturers, IntegriChain's solutions and services enable manufacturers to get their therapies to the right patients at the right time. IntegriChain's Operational Consulting team offers broad operational and decision support practice areas that ensure commercialization and access strategies are put into action and deliver the expected results:

關於 IntegriChain 的諮詢服務
IntegricHain是衆多藥品製造商的藥品商業化合作夥伴。從幫助新興公司計劃和執行首次發佈到爲前50大製造商中的65%以上提供支持,IntegriChain的解決方案和服務使製造商能夠在正確的時間將療法提供給正確的患者。IntegricHain的運營諮詢團隊提供廣泛的運營和決策支持業務領域,確保將商業化和准入策略付諸行動並實現預期的結果:

Roadmap to Launch: a proven blueprint for success in launching a new pharmaceutical product covering commercial analytics and support, compliance programs, and business and process guidance

上市路線圖:成功推出新藥品的行之有效的藍圖,涵蓋商業分析和支持、合規計劃以及業務和流程指導

Contracts & Pricing Consulting: from compliance and business planning to forecasting and analytics

合同和定價諮詢:從合規和業務規劃到預測和分析

Gross-to-Net (GTN) Consulting: includes GTN process assessment, GTN profitability assessment, and GTN modeling

總淨值 (GTN) 諮詢:包括GTN流程評估、GTN盈利能力評估和GTN建模

ICyte Benchmarks: performance metrics based on the industry's largest data set for thousands of therapy brands in the ICyte Platform including point-of-care segmentation and contract benchmarking

iCyte基準測試:績效指標基於iCyte平台中數千個治療品牌的業界最大數據集,包括牀旁細分和合同基準測試

About IntegriChain
IntegriChain is the leading provider of revenue optimization technology and insights for the Pharma industry. The company's ICyte data-driven commercialization platform enables manufacturers to develop, implement, and operate sustainable growth strategies for life-changing science. Through its unique focus on data, SaaS and BPaaS technology, consulting, and outsourcing, IntegriChain helps manufacturers connect the commercial, financial, and operational dimensions of drug access – all the way from demand through to net revenue optimization. IntegriChain is backed by Nordic Capital, a leading sector-specialized private equity investor with a broad portfolio in Healthcare and Technology. IntegriChain's umbrella of companies include Blue Fin Group and Federal Compliance Solutions, and the company is headquartered in Philadelphia, PA, with offices in Ambler, PA, and Pune, India. For more information, visit or follow on LinkedIn.

關於 IntegriChain
IntegricHain是製藥行業收入優化技術和見解的領先提供商。該公司的iCyte數據驅動的商業化平台使製造商能夠爲改變生活的科學制定、實施和運營可持續增長戰略。通過對數據、SaaS和BPaaS技術、諮詢和外包的獨特關注,IntegriChain幫助製造商將藥品准入的商業、財務和運營層面聯繫起來,從需求到淨收入優化。IntegriChain由Nordic Capital提供支持,Nordic Capital是一家領先的專業領域私募股權投資者,在醫療保健和技術領域擁有廣泛的投資組合。IntegricHain的旗下公司包括藍鰭集團和聯邦合規解決方案,該公司總部位於賓夕法尼亞州費城,在賓夕法尼亞州安布勒和印度浦那設有辦事處。欲了解更多信息,請訪問或關注領英。

Contact
Jennifer Guinan | Sage Strategic Marketing | [email protected]

聯繫我們
詹妮弗·吉南 | Sage 戰略營銷 | [電子郵件保護]

SOURCE IntegriChain

來源 IntegricHain

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

想在 PRNEWSWIRE.COM 上刊登貴公司的新聞嗎?

440k+
440k+

Newsrooms &
新聞編輯室和

Influencers
有影響力的人
9k+
9k+

Digital Media
數字媒體

Outlets
網點
270k+
270k+

Journalists
記者

Opted In
選擇加入
GET STARTED
開始吧
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論